Ophthalmoplegic Migraine: Amelioration by Flufenamic acid, a Prostaglandin inhibitor

Abstract
Prostaglandins [PG] release (especially PGE1 and PGF2.alpha.) may play a key role in the development of the migrainous attack. Based on this hypothesis a therapeutic trial with flufenamic acid (a prostaglandin inhibitor of the fenamates group) was conducted during 1 yr in 5 patients suffering from recurrent ophthalmoplegic migraine. Migraninous attacks (25) were treated. Of them 22 patients reported marked alleviation of the headaches. In 2 occasions a partial 3rd nerve palsy accompanied the attack.

This publication has 0 references indexed in Scilit: